web analytics
0.3 C
Munich
Sunday, November 27, 2022

Lenzilumab Driving Humanigen Inc (OTCMKTS: HGEN) Fast

Humanigen Inc (OTCMKTS: HGEN) is moving higher fast skyrocketing up the charts in recent weeks as coronavirus continues to spread around the world. Humanigen’s lenzilumab is proving to be effective against cytokine storms, according to a study from scientists at the Mayo Clinic. The Phase 3 trial is ongoing. On June 15 the Company announced data on the first clinical use of lenzilumab. Patients showed rapid clinical improvement with a median time to recovery of five days, median time to discharge of five days and 100% survival to the data cut-off date. HGEN is quickly attracting legions of shareholders.

On Tuesday HGEN applied to have its common stock approved for listing on the Nasdaq Capital Market. The Company’s ability to obtain Nasdaq’s approval of the listing application will require the Company to satisfy a number of conditions, including the effectiveness of the Registration Statement on Form S-1 filed by the Company on June 15, 2020 (File No. 333-239161), and the Company’s ability to meet certain listing criteria including a minimum stock price and total value of public float.

Humanigen Inc (OTCMKTS: HGEN) is a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.

HGEN took off from its $0.30 lows back in March when the Company announced it was actively exploring clinical stage strategies and partnerships to evaluate whether lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF monoclonal antibody, may reduce or prevent cytokine storm resulting from COVID-19 (or coronavirus, also referred to as SARS-CoV-2) infection.

Lenzilumab has come a long way as a treatment for coronavirus since than; on June 15 HGEN announced data on the first clinical use of lenzilumab in 12 COVID-19 patients. The manuscript, titled ‘First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia’ was published online at medRxiv.org (www.medrxiv.org/content/10.1101/2020.06.08.20125369v1). Patients showed rapid clinical improvement with a median time to recovery of five days, median time to discharge of five days and 100% survival to the data cut-off date. Patients also demonstrated rapid improvement in oxygenation, temperature, inflammatory cytokines and key hematological parameters consistent with improved clinical outcomes.

To Find out the inside Scoop on HGEN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

HGEN

On July 7 HGEN announced several executives have been appointed to key positions at Humanigen. Effective immediately, Dale Chappell, MD, MBA, has joined Humanigen to serve as its Chief Scientific Officer, David L. Tousley, CPA, MBA, has joined the company as Chief Accounting and Administrative Officer, Corporate Secretary and Treasurer, and Omar Ahmed, PharmD, has been promoted to the position of Senior Vice President, Clinical, Medical and Scientific Affairs. All three positions report to Cameron Durrant, MD, MBA, Chief Executive Officer, Humanigen.

“We are pleased that both Dr. Chappell and Mr. Tousley, who have previously operated in interim capacities with the Company, have joined us as full-time members of the Humanigen team,” stated Dr. Cameron Durrant. “Their appointments, along with Dr. Ahmed’s promotion, provide us with continuity and ongoing scientific and operational bench strength as we move the company forward. Filling these key leadership roles with proven executives who are highly regarded within the biotechnology sector, and who have been deeply involved with the strategic direction of our company, is a next step in our plan to rapidly grow into an organization committed to bringing important therapies to patients around the globe,” Dr. Durrant concluded.

We have a Monster Pick Coming. Subscribe Right Now!

Currently racing up the charts HGEN already has the look and feel of a big board stock already since applying to have its common stock approved for listing on the Nasdaq Capital Market. It’s easy to get excited about HGEN here; Humanigen’s lenzilumab is proving to be effective against cytokine storms, according to a study from scientists at the Mayo Clinic. The Phase 3 trial is ongoing. On June 15 the Company announced data on the first clinical use of lenzilumab. Patients showed rapid clinical improvement with a median time to recovery of five days, median time to discharge of five days and 100% survival to the data cut-off date. The lenzilumab story is starting to get picked up by main stream press with a recent mention in CNN and FOX. Eerlier this month the Company completed a $71,800,000 equity financing with J.P. Morgan Securities LLC iacting as the placement agent with a group of healthcare investors including Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), HealthCor, Valiant Capital Partners, First Light Asset Management and Ghost Tree Capital. We will be updating on HGEN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HGEN.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in HGEN either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.